FP457MULTICENTER, PROSPECTIVE, RANDOMISED, CROSSOVER TRIAL TO DEMONSTRATE THE BENEFITS OF HEMODIALYSIS WITHOUT ACETATE (WITH CITRATE): ABC-TREAT STUDY

Abstract

INTRODUCTION AND AIMS: Dialysis fluid, essential element in hemodialysis (HD), is manufactured in situ by the monitors by mixing 3 basic components: treated water, bicarbonate concentrate and acid concentrate. At present we have 2 types of acid concentrate: acetate and citrate. Citrate binds calcium and is rapidly metabolized in liver. OBJECTIVE: To evaluate the impact of HD with citrate on calcium metabolism, acid base status, inflammation, coagulation and hemodynamic stability compared to HD with acetate.METHODS: Multicenter, prospective, randomized and crossover study, 32 weeks, 16 with 3 mmol/l acetate (SoftPac®), and 16 weeks with 1 mmol/l citrate without acetate (SelectBag Citrate®). NCT03319680.Inclusion criteria: adults in HD for at least 3 months by arteriovenous fistula, and sign informed consent. Exclusion criteria: allergy or intolerance to citrate, intercurrent inflammatory diseases, significant cognitive impairment.Epidemiological, dialysis, and biochemical data were collected. Visual clotting scores of the dialyser and venous chambers were quantified.